articleScience AdvancesJan 7, 2026GOLD OA

Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma

AMAkhilesh MishraASAjay SharmaKGKuldeep GuptaDSDhanush S. BankaBABurles A. Johnson

Johns Hopkins University · Johns Hopkins Medicine · +1 more institution

PubMed
Indexed incrossrefdoajpubmed

Abstract

Optimizing dosing strategies is critical to balance effectiveness and toxicity, especially for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study evaluates whether positron emission tomography (PET) imaging targeting Nectin-4 can noninvasively quantify the real-time interaction of the ADC enfortumab vedotin (EV) with tumors in urothelial carcinoma. Using the imaging agent [ 68 Ga]AJ647, dynamic changes in the interaction of EV with Nectin-4 were measured across preclinical models and correlated with therapeutic responses. PET imaging identified dose-dependent variations in Nectin-4 engagement, with suboptimal EV doses resulting in incomplete Nectin-4 engagement and…

Citation impact

5
total citations
FWCI
101.96
Percentile
100%
References
32
Too recent for citation history.

Authors

9

Topics & keywords

Topics
Keywords
  • Dosing
  • Pet imaging
  • Positron emission tomography
  • Therapeutic drug monitoring
  • Therapeutic index
  • Therapeutic effect
  • Drug
  • Urothelial carcinoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding